# Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

> **NCT05435248** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 354 (estimated)

## Conditions studied

- Advanced or Metastatic NSCLC

## Interventions

- **DRUG:** HS-10375

## Key facts

- **NCT ID:** NCT05435248
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-02
- **Primary completion:** 2025-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 354 (ESTIMATED)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05435248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05435248, "Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05435248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*